A clinical trial from Duffy et al. also found that tremelimumab (ancti-CTLA4) combined with ablation is a potential treatment for advanced HCC and leads to the accumulation of CD8+ T cells (41). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.